Online citations, reference lists, and bibliographies.
← Back to Search

Obesity, Insulin Resistance, And Cardiovascular Disease.

G. Reaven, F. Abbasi, T. McLaughlin
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The ability of insulin to stimulate glucose disposal varies more than six-fold in apparently healthy individuals. The one third of the population that is most insulin resistant is at greatly increased risk to develop cardiovascular disease (CVD), type 2 diabetes, hypertension, stroke, nonalcoholic fatty liver disease, polycystic ovary disease, and certain forms of cancer. Between 25-35% of the variability in insulin action is related to being overweight. The importance of the adverse effects of excess adiposity is apparent in light of the evidence that more than half of the adult population in the United States is classified as being overweight/obese, as defined by a body mass index greater than 25.0 kg/m(2). The current epidemic of overweight/obesity is most-likely related to a combination of increased caloric intake and decreased energy expenditure. In either instance, the fact that CVD risk is increased as individuals gain weight emphasizes the gravity of the health care dilemma posed by the explosive increase in the prevalence of overweight/obesity in the population at large. Given the enormity of the problem, it is necessary to differentiate between the CVD risk related to obesity per se, as distinct from the fact that the prevalence of insulin resistance and compensatory hyperinsulinemia are increased in overweight/obese individuals. Although the majority of individuals in the general population that can be considered insulin resistant are also overweight/obese, not all overweight/obese persons are insulin resistant. Furthermore, the cluster of abnormalities associated with insulin resistance - namely, glucose intolerance, hyperinsulinemia, dyslipidemia, and elevated plasma C-reactive protein concentrations -- is limited to the subset of overweight/obese individuals that are also insulin resistant. Of greater clinical relevance is the fact that significant improvement in these metabolic abnormalities following weight loss is seen only in the subset of overweight/obese individuals that are also insulin resistant. In view of the large number of overweight/obese subjects at potential risk to be insulin resistant/hyperinsulinemic (and at increased CVD risk), and the difficulty in achieving weight loss, it seems essential to identify those overweight/obese individuals who are also insulin resistant and will benefit the most from weight loss, then target this population for the most-intensive efforts to bring about weight loss.
This paper references
10.1152/AJPENDO.1985.248.3.E286
Relationship between degree of obesity and in vivo insulin action in man.
C. Bogardus (1985)
10.1007/BF00404344
Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test
D. Pei (2004)
10.2337/diab.17.9.560
Study of the Relationship Between Glucose and Insulin Responses to an Oral Glucose Load in Man
G. Reaven (1968)
10.1002/j.1550-8528.1996.tb00274.x
Immunoassay of endogenous plasma insulin in man.
R. Yalow (1960)
10.2337/diab.30.5.387
Assessment of Insulin Resistance with the Insulin Suppression Test and the Euglycemic Clamp
M. Greenfield (1981)
Varying body mass index cutoff points to describe overweight prevalence among US adults: NHANES III
RJ Kuczmarski (1997)
10.1001/JAMA.282.16.1576
Are health care professionals advising obese patients to lose weight?
D. Galuska (1999)
Immunoassay of endogenous insulin in man
RS Yalow (1960)
10.1172/JCI107560
Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects.
J. Olefsky (1974)
10.1093/OXFORDJOURNALS.AJE.A117385
Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men.
E. Rimm (1995)
10.2337/diab.33.7.622
A Comparison of the Relative Effects of Obesity and Non-insulin-dependent Diabetes Mellitus on In Vivo Insulin-stimulated Glucose Utilization
C. Hollenbeck (1984)
10.1016/S0026-0495(99)90195-6
Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited.
I. Zavaroni (1999)
10.1053/META.2001.24210
Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women.
T. McLaughlin (2001)
10.1161/01.ATV.19.11.2818
Comparison of plasminogen activator inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women.
F. Abbasi (1999)
10.7326/0003-4819-134-4-200102200-00011
Use of Prescription Weight Loss Pills among U.S. Adults in 19961998
L. K. Khan (2001)
10.1161/01.CIR.0000041046.32962.86
Differentiation Between Obesity and Insulin Resistance in the Association With C-Reactive Protein
T. McLaughlin (2002)
10.1002/J.1550-8528.1997.TB00575.X
Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994).
R. Kuczmarski (1997)
10.7326/0003-4819-98-5-855
Weight and hypertension.
R. Havlik (1983)
10.1210/JCEM.84.2.5441
Differences in insulin resistance do not predict weight loss in response to hypocaloric diets in healthy obese women.
T. McLaughlin (1999)
10.1210/JCEM.83.8.5005
Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease.
J. Yip (1998)
10.2337/diab.37.12.1595
Role of Insulin Resistance in Human Disease
G. Reaven (1988)
10.2337/diab.20.2.99
Influence of Nutritional Factors on Prevalence of Diabetes
K. West (1971)
10.1172/JCI104676
Forearm metabolism in obesity and its response to intra-arterial insulin. Characterization of insulin resistance and evidence for adaptive hyperinsulinism.
D. Rabinowitz (1962)
10.1172/JCI106433
Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes.
S. W. Shen (1970)
10.1201/9780203910382.CH7
Insulin Resistance, Compensatory Hyperinsulinemia, and Coronary Heart Disease: Syndrome X
G. Reaven (2002)
10.1016/S0140-6736(65)91026-3
CRITICAL FACTORS IN EXCESSIVE SERUM-INSULIN RESPONSE TO GLUCOSE. OBESITY IN MATURITY-ONSET DIABETES AND GROWTH HORMONE IN ACROMEGALY.
J. Karam (1965)
10.1210/JCEM.86.8.7763
Insulin resistance as a predictor of age-related diseases.
F. Facchini (2001)
10.1016/S0735-1097(02)02051-X
Relationship between obesity, insulin resistance, and coronary heart disease risk.
F. Abbasi (2002)
10.1210/JCEM.76.1.8421101
Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance.
G. Reaven (1993)



This paper is referenced by
10.26481/dis.20200828ap
Vitamin D in insulin sensitivity and obesity: Fact or fiction?
A. Pramono (2020)
Drosophila against the Effects of Caloric Overload in Role of Fat Body Lipogenesis in Protection Metabolism
Thomas J Baranski (2013)
10.5539/JFR.V2N5P1
Effects of Two Hypocaloric Diets Supplemented With White Lupine or Oats on Lipid Peroxidation, Reverse Cholesterol Transport and Paraoxonase Activity in Obese Rat
Fatima Zohra Chabane (2013)
10.3122/JABFM.18.6.491
Risk indices associated with the insulin resistance syndrome, cardiovascular disease, and possible protection with yoga: a systematic review.
K. Innes (2005)
10.1007/978-3-030-11748-1_1
Quantification of Insulin Action in Human Subjects
Andrew J. Krentz (2019)
10.1186/1755-8794-3-3
Association of adipocyte genes with ASP expression: a microarray analysis of subcutaneous and omental adipose tissue in morbidly obese subjects
Robin E. MacLaren (2008)
10.1038/oby.2006.277
Why Visceral Fat is Bad: Mechanisms of the Metabolic Syndrome
R. Bergman (2006)
10.1093/ajcn/nqy331
Apolipoprotein M: a novel adipokine decreasing with obesity and upregulated by calorie restriction.
Veronika Šrámková (2019)
Role of the carotid body in metabolic disturbances
Maria J Ribeiro (2016)
10.1146/ANNUREV.PUBLHEALTH.26.021304.144415
Competing dietary claims for weight loss: finding the forest through truculent trees.
D. Katz (2005)
10.1002/9781444347319.CH6
Assessment of Insulin Sensitivity
J. Szendroedi (2011)
10.1039/c0fo00103a
Anti-inflammatory activity of natural dietary flavonoids.
M. Pan (2010)
Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.
M. Gad (2010)
REPORTS : CARDIOVASCULAR DISEASE IN MINORITY POPULATIONS IMPACT OF BREATHING AWARENESS MEDITATION ON AMBULATORY BLOOD PRESSURE AND SODIUM HANDLING IN PREHYPERTENSIVE AFRICAN AMERICAN ADOLESCENTS
V. Barnes (2008)
10.2337/DIACARE.28.10.2546
Insulin sensitivity and associated risk factors in Mexican children and adolescents.
R. Cisneros-Tapia (2005)
10.1371/journal.pone.0061740
Drosophila Ste-20 Family Protein Kinase, Hippo, Modulates Fat Cell Proliferation
Hongling Huang (2013)
10.1111/jpc.13528
Associations between arterial structure and function and serum levels of liver enzymes in obese adolescents
E. Man (2017)
10.33678/COR.2011.051
Prevence aterosklerózy u dětí
M. Aschermann (2011)
Original Contribution MULTIPLE APPROACHES IN INITIAL OBESITY TREATMENT
A. Shishkova (2008)
10.1186/1475-2840-6-4
Utility of the modified ATP III defined metabolic syndrome and severe obesity as predictors of insulin resistance in overweight children and adolescents: a cross-sectional study
S. Dhuper (2007)
10.1111/j.1440-1681.2011.05638.x
Unmasking the janus faces of autophagy in obesity‐associated insulin resistance and cardiac dysfunction
X. Xu (2012)
10.1016/j.brainres.2008.07.126
Appetite regulatory mechanisms and food intake in mice are sensitive to mismatch in diets between pregnancy and postnatal periods
Dyan Sellayah (2008)
A systems biological perspective on complex human diseases: uncovering hidden relations via multi-scale network analyses
Mara L. Hartsperger (2011)
10.1111/j.1745-7599.2005.00083.x
Central Obesity, the Metabolic Syndrome, and Plasminogen Activator Inhibitor‐1 in Young Adults
S. Appel (2005)
Preventive effect of Aster tataricus on oxidative stress and biomarker of renal function in rat fed with high fat diet and sucrose diet
X. Yao (2017)
10.1620/TJEM.206.23
Liver fat content measured by magnetic resonance spectroscopy at 3.0 tesla independently correlates with plasminogen activator inhibitor-1 and body mass index in type 2 diabetic subjects.
M. Ishii (2005)
OBESIDAD: EPIDEMIA DEL NUEVO MILENIO
G. Lastra (2005)
10.1177/0269881106069467
Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study
M. Rettenbacher (2007)
10.1016/j.jpsychires.2009.01.010
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.
G. Reaven (2009)
10.1210/jc.2013-3698
Bariatric surgery and the mechanism of diabetes remission: are we getting there?
M. Haluzík (2013)
10.1007/s10620-006-9262-6
Association Among C-Reactive Protein, Fatty Liver Disease, and Cardiovascular Risk
J. Lizardi-Cervera (2006)
10.1007/978-1-4614-7318-3_7
Metabolic Syndrome as a Risk Factor for Stroke
A. Farooqui (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar